How to Detect and Treat Difficult Cancers – MD Anderson Cancer Center
MD Anderson Cancer Center shared a post on LinkedIn:
“Four new studies from MD Anderson shed light on how we might detect and treat difficult cancers more effectively, including:
1. A large study led by Dr. Suresh Chari revealed one in 160 patients with new-onset diabetes developed pancreatic cancer within three years, suggesting that in some cases the cancer may actually cause the diabetes.”
Title: Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study
Authors: Suresh T. Chari, Bechien Wu, Camden Lopez, Eva Lustigova, Qiaoling Chen, Stephen K. Van Den Eeden, Amethyst D. Leimpeter, William Fisher, Amy Wood, Ashley S. Alexander, John Valenta, Santhi Swaroop Vege, Erin E. Carlson, Kari G. Rabe, Phil A. Hart, Lu Qian, Ying-Qi Zhao, Nadia Yosuf, Lynn Matrisian, Barbara Kenner, Jo Ann Rinaudo, Anirban Maitra, Ziding Feng
Read the Full Article on Gastroenterology
“2. Patients with KRAS-mutant non-small cell lung cancer and KEAP1/LKB1 co-mutations often face poor outcomes. A study led by Dr. John Heymach found they may respond better to ATR inhibitors, especially when combined with immunotherapy or chemotherapy.”
Title: KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer
Authors: Ana Galan-Cobo, Natalie I. Vokes, Yu Qian, David Molkentine, Kavya Ramkumar, Alvaro G. Paula, Marlese Pisegna, Daniel J. McGrail, Alissa Poteete, Sungnam Cho, Minh Truong Do, Amirali Karimi, Yifan Kong, Anisha Solanki, Ankur Karmokar, Nicolas Floc’h, Adina Hughes, Rebecca Sargeant, Lucy Young, Li Shen, Gozde Kar, Caezaan Keshvani, Claudio Arrechedera, Sharia Hernandez, Katharina Schlacher, Jing Wang, Sonia Iyer, James Conway, Mohamed Reda Keddar, Marta Milo, Ilario de Toma, Susan E. Critchlow, J. Carl Barrett, Jan Cosaert, Alan Lau, Viia Valge-Archer, Lauren A. Byers, Simon T. Barry, John V. Heymach
Read the Full Article on Cancer Cell
“3. TP53 mutations are tough to treat in leukemia. Dr. Bing Carter and Dr. Michael Andreeff found that rezatapopt can restore some p53 function in Y220C mutations. When combined with other inhibitors, it showed stronger anti-leukemia effects.”
Title: Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia
Authors: Bing Z Carter, Po Yee Mak, Edward Ayoub, Xiaogang Wu, Baozhen Ke, Yuki Nishida, Andrew Futreal, Lauren B Ostermann, Andrea D Bedoy, Steffen Boettcher, Courtney D. DiNardo, Anna Puzio-Kuter, Masha V Poyurovsky, Arnold J. Levine, Michael Andreeff
Read the Full Article on Blood
“4. A Phase Ib trial led by Dr. Sarina Piha-Paul, MD tested a combination of pembrolizumab and bacteria Clostridium novyi-NT in patients with treatment-resistant solid tumors. The bacteria-immunotherapy combo helped activate T cells and triggered tumor responses in several patients, including one complete response.”
Title: Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors
Authors: Blessie Elizabeth Nelson, Filip Janku, Siqing Fu, Ecaterina E. Dumbrava, David S. Hong, Daniel D. Karp, Aung Naing, Jordi Rodon, Apostolia M. Tsimberidou, Ravi Murthy, Rahul A. Sheth, Rodabe N. Amaria, Anthony P. Conley, Senthil Damodaran, Kanwal P.S. Raghav, Nicoleta Carapanceanu, Mahendra Pal Singh, Valentin Carapanceanu, Abdulmohammad Pezeshki, Alexey A. Leontovich, Brent L. Kreider, David Tung, Mary Varterasian, Khashayarsha Khazaie, Sarina A. Piha-Paul
Read the Full Article on Clinical Cancer Research
More posts featuring MD Anderson Cancer Center.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023